
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you open and fund a new account within 30 days
- Access to a financial planner
Compass Pathways (CMPS) is a leading medical care facilities business based in the US. It opened the day at $2.71 after a previous close of $2.70. During the day the price has varied from a low of $2.66 to a high of $2.86. The latest price was $2.85 (25 minute delay). Compass Pathways is listed on the NASDAQ and employs 166 staff. All prices are listed in US Dollars.
We currently don't have that product, but here are others to consider:
How we picked theseThe Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
52-week range | $2.56 - $9.97 |
---|---|
50-day moving average | $3.76 |
200-day moving average | $5.34 |
Wall St. target price | $17.56 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-2.30 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.85 from 2025-04-10
1 week (2025-04-04) | 5.17% |
---|---|
1 month (2025-03-12) | -23.59% |
3 months (2025-01-10) | -19.26% |
6 months (2024-10-11) | -52.66% |
1 year (2024-04-12) | -67.09% |
---|---|
2 years (2023-04-12) | -71.67% |
3 years (2022-04-12) | 12.45 |
5 years (2020-04-08) | N/A |
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -40.11% |
Return on equity TTM | -81.55% |
Profit margin | 0% |
Book value | $2.26 |
Market Capitalization | $251.1 million |
TTM: trailing 12 months
We're not expecting Compass Pathways to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Compass Pathways's shares have ranged in value from as little as $2.56 up to $9.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Compass Pathways's is 2.347. This would suggest that Compass Pathways's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Compass Pathways's beta into context you can compare it against those of similar companies.
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom. .
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.